1 min read
Chemomab Therapeutics Posts $5.1 Million Third-Quarter Net Loss
The loss was less than $0.01 per basic and diluted ordinary share. Cash, cash equivalents and short-term bank deposits totaled $4.7 million as of Sept. 30, 2026.

Chemomab Therapeutics Ltd. (CMMB) posted a $5.1 million net loss for the third quarter of 2026, while its cash, cash equivalents and short-term bank deposits fell to $4.7 million as of Sept. 30.
The loss was less than $0.01 per basic and diluted ordinary share. Chemomab recorded a $1.7 million net loss in the comparison period.
The company had $6.7 million in cash, cash equivalents and short-term bank deposits as of June 30, 2026.